Caladrius Biosciences, Inc. (CLBS) News

Caladrius Biosciences, Inc. (CLBS): $0.54

0.01 (+2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLBS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 449

in industry

Filter CLBS News Items

CLBS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLBS News Highlights

  • For CLBS, its 30 day story count is now at 3.
  • Over the past 9 days, the trend for CLBS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CLBS are BIO, NYC and LGVN.

Latest CLBS News From Around the Web

Below are the latest news stories about Caladrius Biosciences Inc that investors may wish to consider to help them evaluate CLBS as an investment opportunity.

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

Girolamo brings legal, finance and M&A experience to cell therapy companyMIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently servin

Yahoo | February 17, 2022

Caladrius Biosciences to Present at the BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

GlobeNewswire | February 8, 2022

Dawson James Remains a Hold on Caladrius Biosciences (CLBS)

Dawson James analyst Jason Kolbert maintained a Hold rating on Caladrius Biosciences (CLBS – Research Report) on December 10. The company's shares closed last Tuesday at $1.03, close to its 52-week low of $0.82. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The the analyst consensus on Caladrius Biosciences is currently a Hold rating.

Brian Anderson on TipRanks | January 5, 2022

Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022

BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms. Biotech Showcase (January 10–12, 2022 and January 17–19, 2022

Yahoo | January 4, 2022

Do Options Traders Know Something About Caladrius (CLBS) Stock We Don't?

Investors need to pay close attention to Caladrius (CLBS) stock based on the movements in the options market lately.

Yahoo | December 22, 2021

-$0.14 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter

Brokerages expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS) will report earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.16). Caladrius Biosciences posted earnings per share []

Dakota Financial News | December 4, 2021

Zacks: Brokerages Anticipate Caladrius Biosciences, Inc. (NASDAQ:CLBS) Will Post Earnings of -$0.14 Per Share

Equities research analysts expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS) will post earnings per share of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Caladrius Biosciences earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.11). Caladrius Biosciences reported earnings of ($0.28) []

Transcript Daily | November 19, 2021

Caladrius Biosciences (NASDAQ:CLBS) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product []

Transcript Daily | November 14, 2021

Caladrius Biosciences (NASDAQ:CLBS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Caladrius Biosciences (NASDAQ:CLBS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01, MarketWatch Earnings reports. During the same period in the prior year, the company earned ($0.29) earnings per share. Shares of NASDAQ:CLBS traded down $0.04 on […]

Dakota Financial News | November 6, 2021

Caladrius Biosciences (NASDAQ:CLBS) Posts Earnings Results, Beats Estimates By $0.01 EPS

Caladrius Biosciences (NASDAQ:CLBS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts consensus estimates of ($0.13) by $0.01, MarketWatch Earnings reports. During the same quarter in the prior year, the business earned ($0.29) EPS. Shares of CLBS traded down $0.04 during trading hours on []

Dakota Financial News | November 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6022 seconds.